
Opinion|Videos|February 17, 2025
Bispecific Antibodies in the Relapsed/Refractory DLBCL Treatment Landscape
A discussion of major challenges in using bispecific antibodies in the relapsed/refractory DLBCL setting, focusing on dosing, safety concerns like CRS, and step-up dosing strategies, along with insights on best practices for community clinics; followed by a review of sequencing bispecific antibodies and CAR T-cell therapies in third-line treatment, informed by recent studies on bispecific/CAR T sequencing
Advertisement
Video content above is prompted by the following:
What are major challenges present when using bispecific antibodies in the RR setting of DLBCL?
- Please discuss challenges associated with dosing as well as safety concerns and discuss how they can be managed.
- Step-up dosing (
Dickinson et al. NEJM 2022 ); CRS (Falchi et al. ASH 2023 )
- Step-up dosing (
- What insights can you offer community clinics with regards to best practices when using and initiating bispecific antibodies?
ALL: Please share your thoughts on sequencing bispecific antibodies in the 3L setting.
- Review bispecific/CAR T sequencing and share your thoughts:
Haydu and Abramson Blood Adv 2024 ;Haynes et al. ASH 2024
Advertisement
Related to this article

Pertuzumab-qcay is FDA approved for the 3 HER2-positive breast cancer indications of reference pertuzumab.

The European Commission approved daraxonrasib monotherapy for metastatic pancreatic adenocarcinoma after at least 1 prior systemic therapy.

Cretostimogene improved RFS after tumor resection in PIVOT-006, supporting a planned FDA submission for NMIBC.

The FDA approved giredestrant plus everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.

The Pan-Mass Challenge donated a record $80 million to Dana-Farber Cancer Institute to support cancer research, treatment, and patient care.

Onvansertib plus FOLFIRI/bevacizumab earned fast track status in first-line KRAS- or NRAS-mutated metastatic colorectal cancer.

The FDA cited the lack of a significant OS benefit in HARMONi for ivonescimab plus chemotherapy after EGFR TKI therapy in NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Giredestrant Plus Everolimus for ER+/HER2–, ESR1-Mutated Metastatic Breast Cancer
2
Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer
3
Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer
4
Cretostimogene Grenadenorepvec Improves RFS in Intermediate-Risk and High-Grade Ta NMIBC
5

